PE Anti-Perforin antibody [B-D48] (ab47226)
Key features and details
- PE Mouse monoclonal [B-D48] to Perforin
- Suitable for: Flow Cyt (Intra)
- Reacts with: Human
- Conjugation: PE. Ex: 488nm, Em: 575nm
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
PE Anti-Perforin antibody [B-D48]
See all Perforin primary antibodies -
Description
PE Mouse monoclonal [B-D48] to Perforin -
Host species
Mouse -
Conjugation
PE. Ex: 488nm, Em: 575nm -
Specificity
Recognizes human Perforin, a 70 kDa protein.
-
Tested applications
Suitable for: Flow Cyt (Intra)more details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant full length protein corresponding to Human Perforin.
-
Positive control
- Flow Cyt (Intra): YT-Indy cell line
-
General notes
This product was changed from ascites to tissue culture supernatant on 19th June 2019. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute with 1 ml deionised water. -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.30
Preservative: 0.09% Sodium azide
Constituents: 94.91% PBS, 5% BSA -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
B-D48 -
Myeloma
x63-Ag8.653 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab47226 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
Use at an assay dependent concentration.
Use 10 µl to label 106 cells or 100 µl of whole blood. ab91357 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|
Notes |
---|
Flow Cyt (Intra)
Use at an assay dependent concentration. Use 10 µl to label 106 cells or 100 µl of whole blood. ab91357 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|
Target
-
Function
Plays a key role in secretory granule-dependent cell death, and in defense against virus-infected or neoplastic cells. Plays an important role in killing other cells that are recognized as non-self by the immune system, e.g. in transplant rejection or some forms of autoimmune disease. Can insert into the membrane of target cells in its calcium-bound form, oligomerize and form large pores. Promotes cytolysis and apoptosis of target cells by facilitating the uptake of cytotoxic granzymes. -
Involvement in disease
Defects in PRF1 are the cause of hemophagocytic lymphohistiocytosis familial type 2 (FHL2) [MIM:603553]; also known as HPLH2. Familial hemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous, rare autosomal recessive disorder. It is characterized by immune dysregulation with hypercytokinemia and defective natural killer cell function. The clinical features of the disease include fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hypofibrinogenemia, and neurological abnormalities ranging from irritability and hypotonia to seizures, cranial nerve deficits, and ataxia. Hemophagocytosis is a prominent feature of the disease, and a non-malignant infiltration of macrophages and activated T lymphocytes in lymph nodes, spleen, and other organs is also found. -
Sequence similarities
Belongs to the complement C6/C7/C8/C9 family.
Contains 1 C2 domain.
Contains 1 EGF-like domain.
Contains 1 MACPF domain. -
Domain
The C2 domain mediates calcium-dependent binding to lipid membranes. A subsequent conformation change leads to membrane insertion of beta-hairpin structures and pore formation. The pore is formed by transmembrane beta-strands. -
Post-translational
modificationsN-glycosylated. -
Cellular localization
Cytoplasmic granule lumen. Secreted. Cell membrane. Endosome lumen. Stored in cytoplasmic granules of cytolytic T-lymphocytes and secreted into the cleft between T-lymphocyte and target cell. Inserts into the cell membrane of target cells and forms pores. Membrane insertion and pore formation requires a major conformation change. May be taken up via endocytosis involving clathrin-coated vesicles and accumulate in a first time in large early endosomes. - Information by UniProt
-
Database links
- Entrez Gene: 5551 Human
- Omim: 170280 Human
- SwissProt: P14222 Human
- Unigene: 2200 Human
-
Alternative names
- Cytolysin antibody
- FLH2 antibody
- HPLH2 antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab47226 has been referenced in 12 publications.
- Herrera FG et al. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. Int J Radiat Oncol Biol Phys 103:320-334 (2019). PubMed: 30267761
- Lam JKP et al. Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection. Front Microbiol 9:416 (2018). Flow Cyt ; Human . PubMed: 29599759
- Pérez-Antón E et al. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. PLoS Negl Trop Dis 12:e0006480 (2018). PubMed: 29750791
- Egui A et al. Phenotypic and Functional Profiles of Antigen-Specific CD4+ and CD8+ T Cells Associated With Infection Control in Patients With Cutaneous Leishmaniasis. Front Cell Infect Microbiol 8:393 (2018). PubMed: 30510917
- Mateus J et al. Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients. J Immunol 198:3170-3180 (2017). PubMed: 28258194